[Effectiveness of imatinib mesylate in treatment for dermatofibroma protuberans].
Moiseenko
V M
VM
Chudenko
V A
VA
Orlova
R V
RV
Imianitov
E N
EN
Matsko
D E
DE
Gafton
G I
GI
Kochnev
V A
VA
Protsenko
S A
SA
Mikhaĭlichenko
T D
TD
Nogaeva
T Kh
TKh
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D018223:Dermatofibrosarcoma / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology*; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases